Aerodrome: The token release strategy will be determined by a vote from veAERO holders, permitted through AERO Fed
On December 5, the Base Ecological Project Aerodrome announced that it will create the embedded AERO Fed in the original design at 08:00 on December 4, which allows the protocol to dynamically adjust the AERO release rate in the future. AERO Fed will allow veAERO holders to vote on Aerodrome's token release strategy, with voting available weekly through the Aerodrome user interface. The reason is that since Aerodrome was launched in 2023, the release rate of newly issued AERO tokens has been decreasing by 1% every week. As the release rate decreases, however, Aerodrome's Gas fees are gradually increasing. Officials stated that AERO Fed will replace existing emission schedules with a dedicated governance smart contract currently under review by ChainSecurity and Spearbit and offer three choices: increase total supply's weekly emission rate by 0.01%, decrease total supply's weekly emission rate by 0.01%, or keep it unchanged. The maximum emission rate is set at 1% of total supply per week and a minimum of 0.01% per week.
Foresight News notes that AERO Fed functions similarly to a management body with authority to slightly increase or decrease token emission rates (emission rates) during each epoch based on ever-changing market dynamics.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Variational open interest has exceeded $2 billions.
Janus Henderson Macro Head Says Market Is Near Its Top but Cannot Say When
A $5.7 billion patent verdict has been issued, Burford Capital (BUR.US) may receive $1.4 billion, and its share price soared by more than 12%.
Burford Capital Ltd. surged more than 12% on Monday, marking its largest intraday increase since the end of March, after a federal jury delivered a verdict in a patent case involving Apple.
Pfizer (PFE.US), BioNTech (BNTX.US), and Moderna (MRNA.US) seek dismissal of Bayer’s Monsanto mRNA patent lawsuit, but the judge rejects the request
A federal judge in Delaware on Monday rejected the requests from Pfizer, BioNTech, and Moderna to dismiss a lawsuit filed against them by Monsanto, a subsidiary of the German pharmaceutical giant Bayer. The lawsuit concerns these pharmaceutical companies' use of a patent related to mRNA technology.